anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method and application of a vaccine of porcine circovirus type 2 virus-like particles. The preparation method provided by the invention comprises the following steps of: cloning an artificially optimized gene coded with porcine circovirus type 2 Cap protein in a baculovirus vector, transfecting an insect cell sf9 to obtain recombinant baculovirus, and strongly expressing the Cap protein in the cell by infecting high five cells through the recombinant baculovirus. The invention further discloses a method for purifying the virus-like particles rapidly, simply and conveniently. The purifying method provided by the invention comprises the following steps of: centrifugally collecting the high five cells to pre-cool PBS (Phosphate Buffered Saline) re-suspension cells by ice, and cracking a cell suspension cracking solution into clarified liquid by using a cell homogeneous instrument. The virus-like particles are purified through a gel filtrating chromatography method. By using the method provided by the invention, the complex cell cracking solution can be rapidly purified into specific virus-like particle protein, and the purity is above 90%.
The primary goal of this study is to examine the feasibility and efficacy of DCS augmentation to CBT/ERP at the end of the session. The main treatment outcome will be measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The secondary goal of the study is to investigate the safety of DCS in adolescents with OCD. 18 adolescents will be recruited in this study. Patients who are currently on medication therapies for OCD must be stable for at least 12 weeks prior to and during the study.

This study consists of a screening period that contains a 90-minute psycho-educational session and treatment period of up to 5 weeks. During the treatment period, patients will receive ten 60-minute CBT/ERP sessions held twice weekly. At the end of each session, patients will receive a 50 mg dose of DCS. Following the administration of the DCS, patients will be asked to do their best not to ritualize and remain on the Children's Day Unit, where they will be observed and report to the research team if any ritualization has occurred. At the end of study participation, all participants will be offered 10 additional sessions of twice-weekly ERP without DCS administration. All participants will then complete a follow-up visit at 10 weeks after baseline.

The main treatment outcome will be measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The secondary goal of the study is to investigate the safety of DCS in adolescents with OCD. Additionally, we will explore the impact of patient's motivation to change, parental pathology, and family accommodation on the treatment progress and outcome in adolescents.

Present data collected from this protocol show that adolescents who completed and engaged in treatment experienced benefit to the combination of CBT/ERP and DCS. However, this is an unblinded study and the adolescents are receiving an intensive form of CBT/ERP with close monitoring following 2 hours after the administration of the DCS. The positive results may be due to this specific way in which the CBT/ERP was delivered or to the attention paid to participants during treatment sessions and monitoring periods. We recruited 5 additional adolescents diagnosed with OCD to serve as control group participants. These individuals all had a history of failed or partial response to at least one trial of Selective Serotonin Reuptake Inhibitor (SSRI) medication or CBT/ERP. These participants also received ten sessions of twice weekly CBT/ERP delivered exactly as it was previously in this protocol, but without DCS administration. All control participants completed a follow-up visit at 10 weeks after baseline. Due to the small number of control participants, statistical analyses comparing the treatment groups were not completed.
Recovery of dry sorbitol from concentrated aqueous sorbitol solns or sorbitol melts. G3A. is effected by spraying sorbitol soln. (pref. not less than 60% on dry substance) or sorbitol melt on to stirred bed of sorbitol crystals (temp. of mixing zone pref. maintained at 40 degrees C to 90 degrees C). and formed steam opt. removed continuously with warm gases at 60 degrees to 140 degrees C; for single run pref. 50 to 500% sorbitol soln. or melt sprayed on crystals. The dried pure white, odourless product is suitable as a pourable sweetening agent for diabetics or for medicinal purposes. In an example, 80% salt-free sorbitol soln. sprayed on agitated sorbitol crystals maintained at 60-80 degrees C vapourised water being removed. In second zone crystals re-dried and milled, 50% dried sorbitol removed, rest recycled.
The present invention relates to a traditional Chinese medicine preparation for treating slow fetal growth and fetal malnutrition, which takes more than 10 Chinese herbal medicines of pilose Asiabell root, largehead atractylodes rhizome, Chinese angelica, himalayan teasel root etc. as the raw materials. The present invention has the effects of benefiting qi, nourishing blood, quieting spirit and nourishing fetus. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation to treat slow fetal growth and fetal malnutrition. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
The present invention discloses a compound composition with function of promoting bone and joint health and an application thereof. In the present invention, glucosamine is combined with collagen, chondroitin sulfate and traditional Chinese medicine extract to prepare the compound composition with function of promoting bone and joint health. The compound composition can shorten onset time. At the same time, the traditional Chinese medicine extract for treating the bone and joint problems is added, to reduce the market impact of adding only modern joint health ingredients. Moreover, the compound composition disclosed by the present invention can be used as a dietary supplement or health food raw material for preventing or treating moderate to mild osteoarthritis. Thus, the compound composition disclosed by the present invention is suitable for promotion and application.
BACKGROUND: Cathepsin C (CTSC) participates in the development of numerous cancers; however, its function in bladder cancer (BCa) remains largely unknown.
METHODS: Bioinformatics prediction, quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay, and Western blot assay were used to determine CTSC expression in BCa tissues, paracancer tissues, BCa cells, and normal uroepithelial cells (SV-HUC-1). Colony formation, cell counting kit-8 (CCK-8), and Transwell assays were utilised to ascertain the involvement of CTSC in BCa. The effect of CTSC on BCa was further studied in vivo via animal experiments.
RESULTS: CTSC exhibited a heightened expression in BCa cells and tissues; meanwhile, bladder urothelial carcinoma (BLCA) patients with enhanced CTSC expression had a remarkably reduced overall survival than those with low CTSC expression. The overexpression of CTSC substantially enhanced the activity, proliferation, migration, and invasion of BCa cells, whereas its suppression repressed the above biological phenotypes. CTSC could activate the Wnt/β-catenin signalling pathway and upregulate diaphanous-related formin 3 (DIAPH3). CTSC overexpression combined with DIAPH3 knockdown partially reversed the impact of CTSC overexpression on the biological behaviour of BCa cells and the activation of the Wnt/β-catenin signalling pathway.
CONCLUSIONS: CTSC was upregulated in tissues and BCa cells, and high CTSC expression was associated with poor overall survival. CTSC could enhance the activity, proliferation, migration, and invasion of BCa cells via upregulating DIAPH3 and activating the Wnt/β-catenin pathway.
During their in person study visit, participants will complete a brief ( \~5 minute) pre-survey before viewing the CrashCourse and Brain Fly-Through concussion educations. Participants in this group will receive both of these educations in 3D (via a Virtual Reality headset). Participants will then be asked to complete a brief ( \~2 minute) survey to assess their knowledge, self-efficacy, and empathy surrounding concussions.
Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
Hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases, has been observed in clinical trials with KADCYLA [see Adverse Reactions (6.1)]. Serious hepatotoxicity, including 3 fatal cases, has been observed in clinical trials (n=1624) with KADCYLA as single-agent. All fatal cases occurred in MBC clinical trials with KADCYLA, which included severe drug-induced liver injury and associated hepatic encephalopathy. Some of the patients experiencing hepatotoxicity had comorbidities and/or concomitant medications with known hepatotoxic potential.

Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Patients with known active liver disease (such as, hepatitis B virus or hepatitis C virus) were excluded from the EMILIA and KATHERINE studies [see Clinical Studies (14.1)]. Reduce the dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases and/or total bilirubin [see Dosage and Administration (2.2)]. Permanently discontinue KADCYLA treatment in patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN. KADCYLA has not been studied in patients with serum transaminases > 2.5 × ULN or bilirubin > 1.5 × ULN prior to the initiation of treatment.

In clinical trials of KADCYLA, cases of nodular regenerative hyperplasia (NRH) of the liver have been identified from liver biopsies (5 cases out of 1624 treated patients, one of which was fatal). Two of these five cases of NRH were observed in EMILIA and two were observed in KATHERINE [see Adverse Reactions (6.1)]. NRH is a rare liver condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules; NRH may lead to non-cirrhotic portal hypertension. The diagnosis of NRH can be confirmed only by histopathology. NRH should be considered in all patients with clinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on the computed tomography (CT) scan of the liver but with normal transaminases and no other manifestations of cirrhosis. Upon diagnosis of NRH, KADCYLA treatment must be permanently discontinued.
Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
Despite progress in reducing the infant mortality in India, the neonatal mortality decline has been slower, necessitating concerted efforts to achieve Sustainable Development Goal-3. A promising strategy aiming to prevent neonatal sepsis in high-risk, vulnerable, low birth weight neonates through an innovative intervention includes probiotic supplementation. This article communicates the decision by the ProSPoNS trial investigators to establish a Central Endpoint Adjudication Committee (CEAC) as an addendum to the protocol published in Trials in 2021 for the purpose of clarifying the primary outcome. In the published protocol, the study hypothesis and primary objective are based on "sepsis," the primary outcome has been specified as sepsis/PSBI, whereas the sample size estimation was performed based on the "physician diagnosed sepsis." To align all the three above, the investigators meeting, held on 17th-18th August 2023, at MGIMS Sevagram, Wardha, deliberated and unanimously agreed that "physician diagnosed sepsis" is the primary study outcome which includes sepsis/PSBI. The CEAC, chaired by an external subject expert and members including trial statistician, a microbiologist, and all site principal investigators will employ four criteria to determine "physician diagnosed sepsis": (1) blood culture status, (2) sepsis screen status, (3) PSBI/non-PSBI signs and symptoms, and (4) the clinical course for each sickness event. Importantly, this clarification maintains consistency with the approved study protocol (Protocol No. 5/7/915/2012 version 3.1 dated 14 Feb 2020), emphasizing the commitment to methodological transparency and adherence to predefined standards. The decision to utilize the guidance of a CEAC is recommended as the gold standard in multicentric complex clinical trials to achieve consistency and accuracy in assessment of outcomes.Trial registrationClinical Trial Registry of India (CTRI) CTRI/2019/05/019197. Registered on 16 May 2019.
The present invention relates to a radio telephony network ( 1 ) supporting at least one link of a radio channel ( 6 ) for a packet data transmission service. The radio telephony network ( 1 ) comprises a plurality of network controllers (RNC). Each network controller (RNC) is connected, via an interface Iub, to at least one base radio station (B-node) supervising at least one macrocell ( 5   a ). The radio telephony network ( 1 ) additionally comprises at least one base radio microstation (B1-micronode) connected to the network controller (RNC) via an interface Iub of the same type as that connecting the base radio station (B-node) to said controller. The base radio microstation (B1 micronode) supervises at least one microcell ( 5   b ) incorporated in at least one macrocell ( 5   a ). The base radio microstation (B1-micronode) provides the packet data transmission service in the microcell ( 5   b ) on the link of the radio channel ( 6 ).
FIELD: medicine, immunology, vaccines. SUBSTANCE: vaccine has polysaccharide conjugated with protein. Indicated protein and polysaccharide are typical molecules of streptococcus of group B. The used protein is recombinant one S1 and it is encoded by plasmid pJMSI ATCC N 40659. Vaccine induces T-independent immunity against infection caused by streptococcus of group B. Vaccine is able to produce immunity in recipient against infection caused by streptococcus of group B. EFFECT: enhanced effectiveness of vaccine. 8 cl, 6 dwg , 2 tbl
Difficulty finding words is common in patients with aphasia subsequent to left hemisphere stroke. This study will compare two cognitive therapies for the treatment of acquired word finding difficulties. The therapies use different types of cues. All participants will receive both therapies. Participants in this study will undergo a comprehensive and detailed assessment of language and other cognitive skills. The two treatments will be compared for their efficacy.
LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
PURPOSE: A composition for treating or preventng amyloid disease comprising cyclophilin B is provided to form neural plate by being deposited with other substances, thereby effectively treating amyloid disease. CONSTITUTION: A composition for treating or preventng amyloid disease comprising cyclophilin B(CypB) includes protein. The CypB protein has amino acid sequence which is represented by sequence number 1. The composition for treating or preventng amyloid disease comprises nucleic acid having nucleotide sequence which codes the cyclophilin B (CypB) protein. The nucleic acid having the nucleotide sequence which codes the CypB protein has nucleotide sequence which codes the amino acid sequence of the sequence number 1. The nucleic acid having nucleotide sequence which codes the CypB protein has nucleotide sequence of sequence number 2. The nucleic acid having the nucleotide sequence which codes the CypB protein is a CypB protein expression recombinant vector. The CypB protein expression recombinant vector comprises nucleotide sequence which codes the amino acid sequence of the sequence number 1. The CypB protein expression recombinant vector comprises the nucleotide sequence of the sequence number 2.
Use of a LAG-3 protein or derivative thereof for the treatment of a cancer in a subject is described. In certain aspects, the subject has one or more of: a low monocyte count; a Luminal B breast cancer; an age of less than about 85 years; has been previously treated with a CDK4/6 inhibitor; has not previously undergone treatment with a taxane chemotherapy; has an elevated neutrophil to lymphocyte ratio; been diagnosed less than about 5 years ago. In another aspect, the LAG-3 protein or derivative is administered to the subject at a dosage of a molar equivalent of >30 mg to <120 mg of LAG-3 derivative LAG- 3Ig fusion protein IMP321. In a further aspect, the LAG-3 protein, or derivative, is administered to the subject on the same day as a chemotherapy agent. In another aspect, the LAG-3 protein, or derivative, is administered to the subject one or more times in the absence of a chemotherapy agent, after one or more dosages of the LAG-3 protein, or derivative, have been administered to the subject before, with, or after one or more dosages of the chemotherapy agent. In a further aspect, the subject is a hormone receptor-positive HER2-neg/low (HR+/HER2-neg/low) metastatic breast cancer patient, or a metastatic triple negative breast cancer (TNBC) patient.
Mutations in the Kunitz-type serine protease inhibitor HAI-2, encoded by SPINT2, are responsible for the pathogenesis of syndromic congenital sodium diarrhea (SCSD), an intractable secretory diarrhea of infancy. Some of the mutations cause defects in the functionally required Kunitz domain 1 and/or subcellular targeting signals. Almost all SCSD patients, however, harbor SPINT2 missense mutations that affect the functionally less important Kunitz domain 2. How theses single amino acid substitutions inactivate HAI-2 was, here, investigated by the doxycycline-inducible expression of three of these mutants in HAI-2-knockout Caco-2 human colorectal adenocarcinoma cells. Examining protein expressed from these HAI-2 mutants reveals that roughly 50% of the protein is synthesized as disulfide-linked oligomers that lose protease inhibitory activity due to the distortion of the Kunitz domains by disarrayed disulfide bonding. Although the remaining protein is synthesized as monomers, its glycosylation status suggests that the HAI-2 monomer remains in the immature, lightly glycosylated form, and is not converted to the heavily glycosylated mature form. Heavily glycosylated HAI-2 possesses full anti-protease activity and appropriate subcellular targeting signals, including the one embedded in the complex-type N-glycan. As predicted, these HAI-2 mutants cannot suppress the excessive prostasin proteolysis caused by HAI-2 deletion. The oligomerization and glycosylation defects have also been observed in a colorectal adenocarcinoma line that harbors one of these SPINT2 missense mutations. Our study reveals that the abnormal protein folding and N-glycosylation can cause widespread HAI-2 inactivation in SCSD patents.
The invention discloses a bacillus subtilis fixedly planted in a nasal cavity of a pig and application of the bacillus subtilis in antiviral activity. The swine bacillus subtilis NS15 has the preservation number of CGMCC No. 20344. The application of the bacillus subtilis NS15 in preparing a nasal administration preparation for treating and/or preventing porcine epidemic diarrhea virus. The application of the bacillus subtilis NS15 in preparing a probiotic preparation for enhancing the congenital immunity of the nasal mucosa of the pig. In vitro and in vivo experiments firstly prove that the bacillus subtilis NS15 has better adhesion and colonization capacity in nasal mucosa of pigs, can adhere to PEDV by secreting extracellular matrix components, prevents viruses from invading host cells, and can induce piglets to generate high-efficiency nasal mucosa innate immune response. In conclusion, the bacillus subtilis strain is expected to be developed into a probiotic preparation for resisting virus from invading and infecting organisms through nose.
Provided is a series of poly-fluorosubstituted pyrazolopyrimidine compounds or salts, which are Bruton's tyrosine kinase (BTK) inhibitors. Also provided is a combination therapy including the compounds in combination with another targeted drug composition or another drug. The combination therapy has a cooperative effect, inhibits the existence of a tumour better than a single targeted drug, and causes certain tumours to completely disappear. The optimised combination therapy treats drug resistance and cancer recurrence better than a single targeted drug, and the treatment cycle is shorter. The present invention also relates to a combined compound and a pharmaceutical preparation which acts as an active ingredient, said pharmaceutical preparation being safer at a lower dosage and having a cooperative effect efficacy. Also provided is a use of the compounds to treat and inhibit an autoimmune disease or illness, a heterogeneous autoimmune disease or illness, an inflammatory disease, a cancer or an illness.
Elevated levels of homocysteine have been implicated as an important risk factor for cardiovascular and other diseases. A composition for decreasing levels of plasma homocysteine and a method for administering the composition are provided the composition containing dextromethorphan (DM), folic acid and vitamins B 6  and B 12 . The composition provides a synergistic therapeutic effect so that lower amounts of the above ingredients may be employed to minimize any undesirable side effects caused by the use of high levels of a component such as DM. Preferred compositions for cardiovascular diseases further include lecithin, vitamin E, beta-carotene, procyanidins/flavonoids, trimethylglycine, garlic oil and minerals. Other compositions for treating glaucoma include bilberry, bioflavonoids and beta-carotene and for treating tardive dyskinesia include an antioxidant such as grape seed extract and pine bark extract, lecithin and oligomeric proanthocyanidins. The compositions may be administered using any suitable means such as orally or intravenous.
A novel human immunodeficiency virus type 1 (HIV-1) isolate, designated lymphadenopathy-associated virus strain MAL, or LAV MAL , was molecularly cloned and characterized. Nucleotide sequence analysis demonstrated that the viral genome of LAV MAL  is 9229 nucleotides long. This retrovirus contains the canonical gag, pol, and env genes, as well as ancillary genes encoding Vif (or Q), Vpr (or R), Tat (or S), and Nef (or F). This virus differs significantly, at both the nucleotide and amino acid sequence levels, from prototypical HIV isolates (e.g., HTLV-III, LAV BRU , and ARV). DNA fragments corresponding to the various gene products and regulatory regions are disclosed. These fragments are useful, inter alia, as probes in diagnostic assays and for the generation of recombinant proteins.